pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
dabigatran etexilate accord
accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - antitrombotiska medel - prevention of venous thromboembolic events.
dabigatran etexilate glenmark 110 mg kapsel, hård
glenmark arzneimittel gmbh - dabigatranetexilatmesilat - kapsel, hård - 110 mg - dabigatranetexilatmesilat 126,83 mg aktiv substans; propylenglykol hjälpämne; mannitol hjälpämne
dabigatran etexilate glenmark 75 mg kapsel, hård
glenmark arzneimittel gmbh - dabigatranetexilatmesilat - kapsel, hård - 75 mg - mannitol hjälpämne; propylenglykol hjälpämne; dabigatranetexilatmesilat 86,48 mg aktiv substans
dabigatran etexilate glenmark 150 mg kapsel, hård
glenmark arzneimittel gmbh - dabigatranetexilatmesilat - kapsel, hård - 150 mg - mannitol hjälpämne; dabigatranetexilatmesilat 172,95 mg aktiv substans; propylenglykol hjälpämne